NCT06568302View on ClinicalTrials.gov

The Long-term Safety and Efficacy of SerpinPC in Subjects with Hemophilia Who Completed a Sponsored SerpinPC Clinical Trial

PHASE3TerminatedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

July 11, 2024

Primary Completion Date

January 29, 2025

Study Completion Date

January 29, 2025

Conditions
Hemophilia aHemophilia BHemophilia a with InhibitorHemophilia B with Inhibitor
Interventions
DRUG

SerpinPC

Administered as SC injection.

Trial Locations (2)

0112

ARENSIA Exploratory Medicine LLC, Tbilisi

MD-2025

Institute of Oncology, ARENSIA Exploratory Medicine, Chisinau

Sponsors

Lead Sponsor

ApcinteX Ltd
All Listed Sponsors
collaborator

Centessa Pharmaceuticals plc

INDUSTRY

lead

ApcinteX Ltd

INDUSTRY

NCT06568302 - The Long-term Safety and Efficacy of SerpinPC in Subjects with Hemophilia Who Completed a Sponsored SerpinPC Clinical Trial | Biotech Hunter | Biotech Hunter